Chirag Dagli

Sir, typically, we indicated that we have three months to six months visibility on the pharma business. Can you provide some colour on how the second half of this year, particularly for the pharma business, looks like versus the first half?

Understood, sir. There is nothing unusual happening this year, post the change in ownership. That is a very clear message, sir?

Understood, sir. Okay. And, sir, in one of your slides, you're mentioning that 75% of your active projects are with global innovators, where Suven is a partner of choice. When you say global innovators, do you mean big pharma or emerging biotech companies as well?